CDXS
Price
$2.35
Change
-$0.14 (-5.62%)
Updated
Sep 17, 04:59 PM (EDT)
Capitalization
220.25M
43 days until earnings call
IMUX
Price
$0.83
Change
+$0.02 (+2.47%)
Updated
Sep 17, 04:59 PM (EDT)
Capitalization
76.28M
50 days until earnings call
Interact to see
Advertisement

CDXS vs IMUX

Header iconCDXS vs IMUX Comparison
Open Charts CDXS vs IMUXBanner chart's image
Codexis
Price$2.35
Change-$0.14 (-5.62%)
Volume$6.48K
Capitalization220.25M
Immunic
Price$0.83
Change+$0.02 (+2.47%)
Volume$1.58K
Capitalization76.28M
CDXS vs IMUX Comparison Chart in %
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. IMUX commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Hold and IMUX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (CDXS: $2.49 vs. IMUX: $0.81)
Brand notoriety: CDXS and IMUX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 38% vs. IMUX: 62%
Market capitalization -- CDXS: $220.25M vs. IMUX: $76.28M
CDXS [@Biotechnology] is valued at $220.25M. IMUX’s [@Biotechnology] market capitalization is $76.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.82B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileIMUX’s FA Score has 1 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • IMUX’s FA Score: 1 green, 4 red.
According to our system of comparison, both CDXS and IMUX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 3 TA indicator(s) are bullish while IMUX’s TA Score has 2 bullish TA indicator(s).

  • CDXS’s TA Score: 3 bullish, 6 bearish.
  • IMUX’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, CDXS is a better buy in the short-term than IMUX.

Price Growth

CDXS (@Biotechnology) experienced а +1.63% price change this week, while IMUX (@Biotechnology) price change was -4.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.35%. For the same industry, the average monthly price growth was +5.87%, and the average quarterly price growth was +34.62%.

Reported Earning Dates

CDXS is expected to report earnings on Oct 30, 2025.

IMUX is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDXS($220M) has a higher market cap than IMUX($76.3M). IMUX YTD gains are higher at: -18.500 vs. CDXS (-47.799). CDXS has higher annual earnings (EBITDA): -52.78M vs. IMUX (-105.1M). CDXS has more cash in the bank: 66.3M vs. IMUX (55.3M). IMUX has less debt than CDXS: IMUX (979K) vs CDXS (69M). CDXS has higher revenues than IMUX: CDXS (57.2M) vs IMUX (0).
CDXSIMUXCDXS / IMUX
Capitalization220M76.3M288%
EBITDA-52.78M-105.1M50%
Gain YTD-47.799-18.500258%
P/E RatioN/AN/A-
Revenue57.2M0-
Total Cash66.3M55.3M120%
Total Debt69M979K7,048%
FUNDAMENTALS RATINGS
CDXS vs IMUX: Fundamental Ratings
CDXS
IMUX
OUTLOOK RATING
1..100
871
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
6365
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMUX's Valuation (26) in the Pharmaceuticals Major industry is in the same range as CDXS (39) in the Chemicals Specialty industry. This means that IMUX’s stock grew similarly to CDXS’s over the last 12 months.

IMUX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that IMUX’s stock grew similarly to CDXS’s over the last 12 months.

CDXS's SMR Rating (99) in the Chemicals Specialty industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that CDXS’s stock grew similarly to IMUX’s over the last 12 months.

CDXS's Price Growth Rating (63) in the Chemicals Specialty industry is in the same range as IMUX (65) in the Pharmaceuticals Major industry. This means that CDXS’s stock grew similarly to IMUX’s over the last 12 months.

CDXS's P/E Growth Rating (100) in the Chemicals Specialty industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that CDXS’s stock grew similarly to IMUX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSIMUX
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 8 days ago
86%
Declines
ODDS (%)
Bearish Trend 15 days ago
83%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CSHX68.500.24
+0.35%
Cashmere Valley Bank
PTNDF0.15N/A
N/A
PT Vale Indonesia TBK
TLTZF17.21N/A
N/A
Tele2 AB
VCIGF4.25N/A
N/A
Vitreous Glass Inc.
TGMR0.06N/A
N/A
Troy Gold & Mineral Corp.

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+2.05%
DNLI - CDXS
49%
Loosely correlated
+0.76%
PRAX - CDXS
49%
Loosely correlated
+3.83%
BEAM - CDXS
47%
Loosely correlated
+7.66%
CRSP - CDXS
47%
Loosely correlated
+5.79%
IPSC - CDXS
45%
Loosely correlated
-1.49%
More